Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
For years now, I've advised my readers about how the average retail investor should avoid buying high-tech IPOs when they first start trading. When you buy at the open, you really risk losing your hard-earned money.
Problem is, people just can't wait. They want in - and they want in fast.
But a little patience on the right stocks, and you can still play them post-IPO for big returns. When you wait to buy, you can ride the "bounce back" period to huge gains...
Had you followed this advice with the savvy cloud provider I'll tell you about today, you could have made 863% in just a little over five years. But if you bought at the open, you risked losing more than half your capital.
2020's IPO calendar is filling up fast, which makes this the perfect time to give you the best IPO profit strategy to follow - plus share with you the big post-IPO winner that could still double your money if you buy now...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
